Aromatase inhibitors (AIs ... the previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole) following tamoxifen for 2–3 years (early ...
Early initiation of moderate-intensity aerobic exercise reduced pain compared with standard care among postmenopausal women who received aromatase inhibitors.
[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...
SurvivorNet on MSN6mon
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of KisqaliIn a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...
Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer. Treatment with metronomic capecitabine plus an ...
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
Camizestrant with a CDK 4/6 inhibitor significantly improves progression-free survival in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations. The SERENA-6 trial shows camizestrant's ...
Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback